Lauren P. Wallner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren P. Wallner has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Sarah T. Hawley
Division of General Medicine, Department of Medicine, University of Michigan , Ann Arbor, MI
16 shared publications - Steven J. Katz
Department of Internal Medicine, University of Michigan, Ann Arbor, MI
15 shared publications Ann S. Hamilton
Department of Population and Public Health Sciences, Keck School of Medicine, Los Angeles, USA
14 shared publications- Megan A. Mullins
Department of Health Economics, Systems, and Policy, Peter O'Donnell Jr. School of Public Health University of Texas Southwestern Medical Center Dallas Texas USA
14 shared publications Kevin C. Ward
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA
11 shared publicationsSarah T. Hawley
Department of Internal Medicine and Rogel Cancer Center, University of Michigan, Ann Arbor, USA
11 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in Journal of Pain and Symptom Management
Unplanned Healthcare Use and Self-Efficacy for Managing Symptoms During Oral Anticancer Therapy
- 7 October 2026
- Published by Elsevier in Journal of Pain and Symptom Management
Open AccessUnplanned Healthcare Use and Self-Efficacy for Managing Symptoms During Oral Anticancer Therapy
- Open Access
- 11 May 2026
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (S2) , 2020-2030
Patient-reported duplication and missed breast cancer survivorship care more than 5 years after initial treatment
Purpose: Little is known about the long-term coordination of breast cancer survivorship care, including duplicated and/or missed care and whether disparities exist. We investigated patients’ perceptions of survivorship care coordination more than 5 years post-initial treatment, and examined differences by survivorship care delivery model, and patient characteristics. Methods: The iCanCare study is a longitudinal study of women diagnosed with early-stage breast cancer in 2014–2015 identified in the Los Angeles and Georgia Surveillance, Epidemiology and End Results registries. Women were surveyed during initial treatment and again 6–7 years later (2021–2022) ( N = 1412, 60% response rate). Respondents were asked how often survivorship services were ordered twice (duplication) or key aspects of care were missed, and who led their care delivery. Associations of participant characteristics and survivorship care delivery model with duplication and missed care were estimated using multivariable logistic regression. Results: Overall, 29% of participants reported duplication, and 30% reported missed survivorship care. Latina women (vs. white) and those with 2 or more comorbidities (vs. 0) were more likely to report duplicated care (aOR: 1.71, 95% CI: 1.04–2.80, comorbidities aOR: 2.04, 1.27, 3.26). Women who reported oncologist-led care (vs. PCP-led) were more likely to report duplicated care (aOR: 2.17, 1.40–3.35) but were less likely to report missed care (aOR: 0.62, 0.42, 0.93). Conclusion: A notable proportion of long-term breast cancer survivors reported duplicated and/or missed survivorship care, with Latina women more often reporting duplicated care. Implications for Cancer Survivors: These findings highlight persistent challenges of coordinating long-term survivorship care and the need for scalable strategies and incentives to promote coordination across oncology and primary care teams.
- 11 May 2026
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (S2) , 2020-2030
Open AccessPatient-reported duplication and missed breast cancer survivorship care more than 5 years after initial treatment
Purpose: Little is known about the long-term coordination of breast cancer survivorship care, including duplicated and/or missed care and whether disparities exist. We investigated patients’ perceptions of survivorship care coordination more than 5 years post-initial treatment, and examined differences by survivorship care delivery model, and patient characteristics. Methods: The iCanCare study is a longitudinal study of women diagnosed with early-stage breast cancer in 2014–2015 identified in the Los Angeles and Georgia Surveillance, Epidemiology and End Results registries. Women were surveyed during initial treatment and again 6–7 years later (2021–2022) ( N = 1412, 60% response rate). Respondents were asked how often survivorship services were ordered twice (duplication) or key aspects of care were missed, and who led their care delivery. Associations of participant characteristics and survivorship care delivery model with duplication and missed care were estimated using multivariable logistic regression. Results: Overall, 29% of participants reported duplication, and 30% reported missed survivorship care. Latina women (vs. white) and those with 2 or more comorbidities (vs. 0) were more likely to report duplicated care (aOR: 1.71, 95% CI: 1.04–2.80, comorbidities aOR: 2.04, 1.27, 3.26). Women who reported oncologist-led care (vs. PCP-led) were more likely to report duplicated care (aOR: 2.17, 1.40–3.35) but were less likely to report missed care (aOR: 0.62, 0.42, 0.93). Conclusion: A notable proportion of long-term breast cancer survivors reported duplicated and/or missed survivorship care, with Latina women more often reporting duplicated care. Implications for Cancer Survivors: These findings highlight persistent challenges of coordinating long-term survivorship care and the need for scalable strategies and incentives to promote coordination across oncology and primary care teams.
- Open Access
- 13 February 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (3) , 196
Patient symptoms, confidence, and adherence during the first 8 weeks of targeted oral anticancer agent treatment
Purpose: We aimed to understand patients’ initial experiences with targeted oral anticancer agents (OAAs). We investigated symptoms experienced and how symptom severity affected patient confidence to manage and seek care for symptoms and OAA adherence. Methods: We conducted a longitudinal prospective cohort study of patients during the first 8 weeks of targeted OAA treatment at an NCI-designated cancer center. Participants completed patient-reported outcome measures (PROMs) online at three timepoints. Descriptive statistics quantified demographics, cancer characteristics, symptom severity, confidence, and OAA adherence. Logistic regression was used to estimate confidence and adherence by each symptom at each timepoint. Mixed effects logistic regressions accounted for repeated measures and time effects on outcomes. Results: Participants ( n = 59) reported severe symptoms at all timepoints. Tiredness and drowsiness were most frequently reported as severe. Participants’ confidence increased from timepoint 1 to 3. Most participants reported high confidence (61–86%) and excellent adherence (75–80%) across all timepoints, but 20–25% had less than excellent OAA adherence. High confidence to manage symptoms was positively associated with older age. Confidence to manage symptoms was inversely related to the severity of depression, tiredness, drowsiness, constipation, and tingling/numbness. Conclusion: Confidence to manage symptoms increased with time on OAAs, but severe symptoms persisted. Although self-reported OAA adherence was high, a notable number of participants reported suboptimal adherence. Relationships between confidence, symptom severity, and adherence should be identified in clinical settings to evaluate patients who may need extra clinical support during OAA treatment.
- 13 February 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (3) , 196
Open AccessPatient symptoms, confidence, and adherence during the first 8 weeks of targeted oral anticancer agent treatment
Purpose: We aimed to understand patients’ initial experiences with targeted oral anticancer agents (OAAs). We investigated symptoms experienced and how symptom severity affected patient confidence to manage and seek care for symptoms and OAA adherence. Methods: We conducted a longitudinal prospective cohort study of patients during the first 8 weeks of targeted OAA treatment at an NCI-designated cancer center. Participants completed patient-reported outcome measures (PROMs) online at three timepoints. Descriptive statistics quantified demographics, cancer characteristics, symptom severity, confidence, and OAA adherence. Logistic regression was used to estimate confidence and adherence by each symptom at each timepoint. Mixed effects logistic regressions accounted for repeated measures and time effects on outcomes. Results: Participants ( n = 59) reported severe symptoms at all timepoints. Tiredness and drowsiness were most frequently reported as severe. Participants’ confidence increased from timepoint 1 to 3. Most participants reported high confidence (61–86%) and excellent adherence (75–80%) across all timepoints, but 20–25% had less than excellent OAA adherence. High confidence to manage symptoms was positively associated with older age. Confidence to manage symptoms was inversely related to the severity of depression, tiredness, drowsiness, constipation, and tingling/numbness. Conclusion: Confidence to manage symptoms increased with time on OAAs, but severe symptoms persisted. Although self-reported OAA adherence was high, a notable number of participants reported suboptimal adherence. Relationships between confidence, symptom severity, and adherence should be identified in clinical settings to evaluate patients who may need extra clinical support during OAA treatment.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 3 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Site-specific Cancer Diagnosis After Medicare Eligibility Date using 90% coverage and at least 12-months follow-up
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 3 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Site-specific Cancer Diagnosis After Medicare Eligibility Date using 90% coverage and at least 12-months follow-up
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Background:The US Health Retirement Study (HRS) is an ongoing population-representative cohort of US adults ages >50 with rich data on health during aging. Self-reported cancer diagnoses have been collected since 1998, but they have not been validated. We compared self-reported cancer diagnoses in HRS interviews against diagnostic claims from linked Medicare records.Methods:Using HRS–Medicare linked data, we examined the validity of first incident cancer diagnoses self-reported in biennial interviews from 2000 to 2016 against ICD-9 and ICD-10 diagnostic claim records as the gold standard. Data were from 8,242 HRS participants ages ≥65 with 90% continuous enrollment in fee-for-service Medicare. We calculated the sensitivity, specificity, and κ for first incident invasive cancer diagnoses (all cancers combined, and each of bladder, breast, colorectal/anal, uterine, kidney, lung, and prostate cancers) cumulatively over the follow-up and at each biennial study interview.Results:Overall, self-reports of first incident cancer diagnoses from 2000 to 2016 had 73.2% sensitivity and 96.2% specificity against Medicare claims (κ = 0.73). For specific cancer types, sensitivities ranged from 44.7% (kidney) to 75.0% (breast), and specificities ranged from 99.2% (prostate) and 99.9% (bladder, uterine, and kidney). Results were similar in sensitivity analyses restricted to individuals with 100% continuous fee-for-service Medicare enrollment and when restricted to individuals with at least 24 months of Medicare enrollment.Conclusions:Self-reported cancer diagnoses in the HRS have reasonable validity for use in population-based research that is maximized with linkage to Medicare.Impact:These findings inform the use of the HRS for population-based cancer and aging research.
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Background:The US Health Retirement Study (HRS) is an ongoing population-representative cohort of US adults ages >50 with rich data on health during aging. Self-reported cancer diagnoses have been collected since 1998, but they have not been validated. We compared self-reported cancer diagnoses in HRS interviews against diagnostic claims from linked Medicare records.Methods:Using HRS–Medicare linked data, we examined the validity of first incident cancer diagnoses self-reported in biennial interviews from 2000 to 2016 against ICD-9 and ICD-10 diagnostic claim records as the gold standard. Data were from 8,242 HRS participants ages ≥65 with 90% continuous enrollment in fee-for-service Medicare. We calculated the sensitivity, specificity, and κ for first incident invasive cancer diagnoses (all cancers combined, and each of bladder, breast, colorectal/anal, uterine, kidney, lung, and prostate cancers) cumulatively over the follow-up and at each biennial study interview.Results:Overall, self-reports of first incident cancer diagnoses from 2000 to 2016 had 73.2% sensitivity and 96.2% specificity against Medicare claims (κ = 0.73). For specific cancer types, sensitivities ranged from 44.7% (kidney) to 75.0% (breast), and specificities ranged from 99.2% (prostate) and 99.9% (bladder, uterine, and kidney). Results were similar in sensitivity analyses restricted to individuals with 100% continuous fee-for-service Medicare enrollment and when restricted to individuals with at least 24 months of Medicare enrollment.Conclusions:Self-reported cancer diagnoses in the HRS have reasonable validity for use in population-based research that is maximized with linkage to Medicare.Impact:These findings inform the use of the HRS for population-based cancer and aging research.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 6 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Education Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 6 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Education Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 2 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Overall Cancer Diagnosis After Medicare Eligibility Date using 90% coverage and at least 12-months follow-up
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 2 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Overall Cancer Diagnosis After Medicare Eligibility Date using 90% coverage and at least 12-months follow-up
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 5 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Sex Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 5 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Sex Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 1 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
ICD9 and ICD10 Definitions for Self-Reported Cancer Types in the Health and Retirement Study
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 1 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
ICD9 and ICD10 Definitions for Self-Reported Cancer Types in the Health and Retirement Study
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 4 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Age Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 4 from Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000–2016
Age Stratified Cumulative sensitivity, specificity, and kappa for first incident cancer diagnosis (any cancer, and seven specific cancer types), HRS Medicare enrollees with 90% continuous fee-for-service coverage and at least 12-months of Medicare follow-up, 2000-2016